Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.

By M. Ewer, S. Lippman. Journal of Clinical Oncology, 2005

627 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Dermatology, Oncology

View Paper: https://www.semanticscholar.org/paper/a4fa12989e1e600106837455c5d3ba9241faa5f9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Oncology

Citations in the corpus

From cancer patient to cancer survivor : lost in transition (2006, background): “The cardiac dysfunction associated with anthracycline is potentially irreversible, long term, and capable of appearing years or decades following therapy (Ewer and Lippman, 2005).”
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, methodology): “These agents are now considered to have increased potential for long-term cardiac dysfunction, increased morbidity, and mortality.(10,11)”
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials (2010, background): “These free radicals cause direct damage to proteins, lipids and DNA and most available evidence suggests that myocyte apoptosis is related to increased oxidative stress caused by these processes [7].”
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). (2016, background): “The mechanism of anti-HER2 drug-induced cardiotoxicity includes structural and functional changes in contractile proteins and mitochondria, but it rarely leads to cell death, explaining the potential for reversibility.(53,54) Risk factors for anti-HER2 drug-induced cardiotoxicity include previous ex”
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management (2016, background): “An additional study in leukemia patients suggested that a troponin elevation may identify those at risk for LVD.(131)”
Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. (2014, background): “In contrast, type II cardiomyopathy is not dose-related, may be reversible, and results in no apparent ultrastructural changes (63).”
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, background): “These agents are now considered to have increased potential for long-term cardiac dysfunction, increased morbidity, and mortality.(10,11)”
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (2016, background): “The mechanism of anti-HER2 drug-induced cardiotoxicity includes structural and functional changes in contractile proteins and mitochondria, but it rarely leads to cell death, explaining the potential for reversibility.(53,54) Risk factors for anti-HER2 drug-induced cardiotoxicity include previous ex”
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. (2010, background): “The clinical outcome of patients with TIC is more favorable than that associated with cardiotoxicity from anthracyclines: cardiac function usually recovers after drug withdrawal and initiation of HF therapy.(9-12) The concept that TIC is reversible, however, remains controversial.”